Reminder of Class Action for Nektar Therapeutics Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Should l Buy NKTR?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will not incur any upfront costs, as attorney fees will be covered through a contingency fee arrangement, allowing them to seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that the defendants failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated integrity and prospects of the trial, resulting in investor losses when the truth emerged.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 83.990
Low
102.00
Averages
123.43
High
165.00
Current: 83.990
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Class Action for Nektar Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, to apply as lead plaintiffs by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, allowing them to pursue compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that defendants failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated trial integrity and prospects, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
See More
Class Action Filed Against Nektar Therapeutics
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Nektar Therapeutics, alleging violations of federal securities laws on behalf of all investors who purchased Nektar securities between February 26, 2025, and December 25, 2025.
- Allegation Details: The complaint claims that Nektar's executives failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, likely resulting in significant negative impacts on the trial's outcomes, thus overstating the company's overall prospects.
- Investor Action: Affected investors have until May 5, 2026, to request to be appointed as lead plaintiff, with the law firm operating on a contingency fee basis, ensuring that investors only pay if the case is successful.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman LLC is recognized for its success in recovering hundreds of millions for investors nationwide, emphasizing its expertise in securities fraud class actions and commitment to restoring investor capital.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: Boston Scientific faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, with investors able to file as lead plaintiffs by May 4, 2026, potentially leading to stock price pressure and diminished market confidence.
- Eos Energy Issues: Eos Energy is accused in a class action of failing to ramp up production capacity and experiencing excessive battery line downtime, with a lead plaintiff deadline of May 5, 2026, which could impact future financing and market performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is being sued for concealing safety concerns in its DCCR clinical trial, with investors able to apply as lead plaintiffs by May 5, 2026, and a successful lawsuit could result in significant compensation liabilities and reputational damage for the company.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is facing a lawsuit for not adhering to standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, and if the lawsuit is successful, it could severely impact the company's future R&D and market outlook.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial in its public statements, resulting in investor losses.
- Market Reaction: As the market learned the truth about Nektar, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which undermined investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers legal consultations for global investors and encourages affected shareholders to take action before class certification to ensure their rights are protected.
See More
Reminder for Nektar Therapeutics Class Action Deadline
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, allowing them to seek legal recourse without financial burden.
- Case Background: The lawsuit alleges that the defendants failed to follow applicable instructions and protocols in the REZOLVE-AA trial, leading to overstated integrity and prospects of the trial, resulting in investor losses when the true information was disclosed.
- Law Firm Advantages: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
See More
Reminder of Class Action for Nektar Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, allowing them to seek compensation without financial burden.
- Case Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated trial integrity and resulting in investor losses when the true details were revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
See More
Reminder of Class Action for Nektar Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, to apply as lead plaintiffs by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, allowing them to pursue compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that defendants failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated trial integrity and prospects, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
See More
Class Action Filed Against Nektar Therapeutics
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Nektar Therapeutics, alleging violations of federal securities laws on behalf of all investors who purchased Nektar securities between February 26, 2025, and December 25, 2025.
- Allegation Details: The complaint claims that Nektar's executives failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, likely resulting in significant negative impacts on the trial's outcomes, thus overstating the company's overall prospects.
- Investor Action: Affected investors have until May 5, 2026, to request to be appointed as lead plaintiff, with the law firm operating on a contingency fee basis, ensuring that investors only pay if the case is successful.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman LLC is recognized for its success in recovering hundreds of millions for investors nationwide, emphasizing its expertise in securities fraud class actions and commitment to restoring investor capital.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: Boston Scientific faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, with investors able to file as lead plaintiffs by May 4, 2026, potentially leading to stock price pressure and diminished market confidence.
- Eos Energy Issues: Eos Energy is accused in a class action of failing to ramp up production capacity and experiencing excessive battery line downtime, with a lead plaintiff deadline of May 5, 2026, which could impact future financing and market performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is being sued for concealing safety concerns in its DCCR clinical trial, with investors able to apply as lead plaintiffs by May 5, 2026, and a successful lawsuit could result in significant compensation liabilities and reputational damage for the company.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is facing a lawsuit for not adhering to standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, and if the lawsuit is successful, it could severely impact the company's future R&D and market outlook.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial in its public statements, resulting in investor losses.
- Market Reaction: As the market learned the truth about Nektar, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which undermined investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers legal consultations for global investors and encourages affected shareholders to take action before class certification to ensure their rights are protected.
See More
Reminder for Nektar Therapeutics Class Action Deadline
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, allowing them to seek legal recourse without financial burden.
- Case Background: The lawsuit alleges that the defendants failed to follow applicable instructions and protocols in the REZOLVE-AA trial, leading to overstated integrity and prospects of the trial, resulting in investor losses when the true information was disclosed.
- Law Firm Advantages: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
See More
Reminder of Class Action for Nektar Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, allowing them to seek compensation without financial burden.
- Case Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated trial integrity and resulting in investor losses when the true details were revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
See More
